Skip to Content
Merck
  • A combined approach of vesicle formulations and microneedle arrays for transcutaneous immunization against hepatitis B virus.

A combined approach of vesicle formulations and microneedle arrays for transcutaneous immunization against hepatitis B virus.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences (2012-02-15)
Hoang Hirschberg, Sandra van Kuijk, Jessica Loch, Wim Jiskoot, Joke Bouwstra, Gideon Kersten, Jean-Pierre Amorij
ABSTRACT

In the search for an optimal approach for the transcutaneous immunization (TCI) of hepatitis B surface antigen (HBsAg), two vesicle formulations, L595 vesicles (composed of sucrose-laurate ester and octaoxyethylene-laurate ester) and sPC vesicles (composed of soybean-phosphatidylcholine and Span-80) were prepared and characterized in vitro and in vivo. HBsAg was associated to the vesicles, resulting in sPC-HBsAg vesicles (±170nm) with 79% HBsAg association and L595-HBsAg vesicles (±75nm) with only 29% HBsAg association. The vesicles induced in mice via TCI an antibody response only when the skin was pretreated with microneedles. This response was improved by the adjuvant cholera toxin. The sPC-HBsAg vesicle formulations showed to be the most immunogenic for TCI, which was related to the higher degree of HBsAg association.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Span® 80, nonionic surfactant
Supelco
Span® 80, viscosity 1000-2000 mPa.s (20 °C)
Supelco
Span® 80, suitable for GC